TGF-β Inhibitor Pipeline Expands with 25+ Companies Developing Novel Therapies for Cancer and Fibrosis
Key Insights
Over 25 pharmaceutical companies are actively developing 30+ TGF-β (search) inhibitors to address significant unmet needs in oncology and fibrosis where existing therapies show limited effectiveness.
Key pipeline advances include Keros Therapeutics initiating Phase III trials for elritercept in myelodysplastic syndromes and EpicentRx (search) receiving FDA Fast Track designation for AdAPT-001 in soft tissue sarcoma.
Recent clinical milestones demonstrate promising efficacy across multiple indications, with companies like Isarna Therapeutics reporting positive Phase II results for retinal fibrosis treatment ISTH0036.
The transforming growth factor-β (TGF-β (search)) inhibitor therapeutic space is experiencing unprecedented growth, with over 25 pharmaceutical companies actively developing more than 30 pipeline candidates to address critical unmet medical needs in oncology and fibrosis. According to DelveInsight's latest pipeline analysis, the market is poised for significant expansion as existing therapies in these areas often demonstrate limited effectiveness.
Pipeline Momentum Builds Across Multiple Indications
The robust development landscape includes leading companies such as EpicentRx (search), Scholar Rock, Sirnaomics, SiSaf, iOnctura, Keros Therapeutics, Isarna Therapeutics, TiumBio (search), Agomab Therapeutics, IO Biotech, Elpiscience Biopharmaceuticals, Jiangsu Hengrui Medicine, Sunshine Lake Pharma, Roche, and Enveda Biosciences. These organizations are advancing promising candidates including AdAPT-001, SRK-181, STP 707, SIS 201 CD, IOA-359, Elritercept, ISTH0036, TU-2218, AGMB-129, IO170, ES 014, SHR-1701, HEC585, RO7204239, and ESN-Y across various clinical development stages.
The therapeutic potential of TGF-β (search) inhibition stems from the pathway's dual role in disease progression. In healthy tissues and early tumor development, TGF-β functions as a tumor suppressor by inducing epithelial growth arrest. However, in advanced cancers, dysregulated TGF-β signaling promotes tumor progression by driving epithelial-to-mesenchymal transition, stimulating angiogenesis, and enabling immune evasion.
Recent Clinical Milestones Signal Progress
Several companies have achieved significant regulatory and clinical milestones in 2025. In July, Keros Therapeutics announced the first patient dosing in the Phase III RENEW clinical trial of elritercept for adults with transfusion-dependent anemia associated with very low, low, or intermediate risk myelodysplastic syndromes. This milestone triggered a $10 million payment to Keros under its global license agreement with Takeda (search).
Isarna Therapeutics reported positive final results from the Phase II BETTER trial in May 2025, evaluating ISTH0036 for retinal fibrosis treatment. ISTH0036 is an investigational antisense oligonucleotide designed to selectively suppress transforming growth factor beta 2 (TGF-β2 (search)) production, a key cytokine involved in fibrosis and disease progression in retinal pathologies.
Diverse Therapeutic Approaches Show Promise
The pipeline encompasses various molecular approaches and administration routes. TiumBio (search) presented updated efficacy data for TU-2218 from a Phase I/II solid tumor trial at the American Society of Clinical Oncology annual meeting in May 2025. Agomab Therapeutics announced interim data from the STENOVA1 Phase IIa trial for AGMB-129, an oral gastrointestinal-restricted small molecule ALK5 (search) inhibitor being developed for Fibrostenosing Crohn's Disease.
IO Biotech demonstrated preclinical efficacy with their TGF-β (search)-directed vaccine IO170, which significantly reduced tumor growth in pancreatic adenocarcinoma and prostate cancer models while reshaping the tumor microenvironment without systemic toxicity. The company is preparing for FDA IND submission.
Regulatory Recognition Validates Approach
The FDA granted Fast Track designation to EpicentRx (search)'s AdAPT-001 in December 2024. This oncolytic adenovirus-delivered TGF-β (search) inhibitor, combined with anti-PD-1 (search) nivolumab or anti-PD-L1 (search) atezolizumab, is being developed for recurrent or refractory advanced or metastatic soft tissue sarcoma with disease progression after at least one prior therapy line.
The pipeline assessment reveals therapeutic candidates spanning discovery through Phase III development, with diverse molecule types including gene therapies, small molecules, vaccines, polymers, peptides, and monoclonal antibodies. Administration routes range from oral and subcutaneous to intravenous and topical formulations, reflecting the versatility of TGF-β (search) targeting strategies.
While EpicentRx (search)'s AdAPT-001 represents the most advanced candidate in Phase II for sarcoma and solid tumors, other promising agents including Sirnaomics' STP 707, SiSaf's SIS 201 CD, iOnctura's IOA-359, and Enveda Biosciences' ESN-Y remain in earlier development stages, suggesting a sustained pipeline of innovation in this therapeutic area.